Takara Bio Board Backs Parent’s Tender Offer, Paving Way for Delisting

Takara Bio Inc. ( (JP:4974) ) has issued an update.

Takara Bio Inc.’s board has endorsed a tender offer by its parent company, Takara Holdings Inc., recommending that shareholders tender their shares at ¥1,150 per share. The move is part of a plan for Takara Holdings to acquire all remaining shares, potentially leading to Takara Bio’s delisting from the Tokyo Stock Exchange and making it a wholly owned subsidiary.

Takara Holdings currently holds a majority stake, and the tender offer has no upper limit on the number of shares to be purchased, increasing the likelihood that free float will fall below listing requirements. If completed as planned, the transaction will end market trading in Takara Bio’s shares and further integrate the biotechnology group within Takara Holdings’ corporate structure, affecting liquidity and governance for existing minority investors.

The most recent analyst rating on (JP:4974) stock is a Sell with a Yen747.00 price target. To see the full list of analyst forecasts on Takara Bio Inc. stock, see the JP:4974 Stock Forecast page.

More about Takara Bio Inc.

Takara Bio Inc. operates in the biotechnology and life sciences sector, focusing on research tools and related services, and is listed on the Prime Market of the Tokyo Stock Exchange. The company is a consolidated subsidiary of Takara Holdings Inc., which already owns about 60.91% of its shares and oversees group management and shared services across its portfolio.

Average Trading Volume: 271,099

Technical Sentiment Signal: Strong Sell

Current Market Cap: Yen98.38B

Learn more about 4974 stock on TipRanks’ Stock Analysis page.